参考文献/References:
[1].Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[2].[2] Lafuente-Lafuente C,Valembois L,Bergmann JF,et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation[J]. Cochrane Database Syst Rev,2015,(3):CD005049.
[3].[3] Gr?nberg T,Hartikainen JE,Nuotio I,et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study[J]. Pacing Clin Electrophysiol,2015,38(3):368-375.
[4].[4] Stiell IG,Sivilotti MLA,Taljaard M,et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation(RAFF2):a partial factorial randomised trial[J]. Lancet,2020,395(10221):339-349.
[5].[5] Hellman T,Kiviniemi T,Vasankari T,et al. Prediction of ineffective elective cardioversion of atrial fibrillation:a retrospective multi-center patient cohort study[J]. BMC Cardiovasc Disord,2017,17(1):33.
[6].[6] Hellman T,Kiviniemi T,Nuotio I,et al. Optimal timing for cardioversion in patients with atrial fibrillation[J].?Clin Cardiol,2018,41(7):966-971.
[7].[7] Kirchhof P,Camm AJ,Goette A,et al. Early rhythm-control therapy in patients with atrial fibrillation[J]. N Engl J Med,2020,383(14):1305-1316.
[8].[8] Kim D,Yang PS,You SC,et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation:nationwide cohort study[J]. BMJ,2021,373:n991.
[9].[9] Pluymaekers NAHA,Dudink EAMP,Luermans JGLM,et al. Early or delayed cardioversion in recent-onset atrial fibrillation[J]. N Engl J Med,2019,380(16):1499-1508.
[10].[10] Lindberg S,Hansen S,Nielsen T. Spontaneous conversion of first onset atrial fibrillation[J].?Intern Med J,2012,42(11):1195-1199.
[11].[11] Danias PG,Caulfield TA,Weigner MJ,et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm[J]. J Am Coll Cardiol,1998,31(3):588-592.
[12].[12] Airaksinen KEJ. Early versus delayed cardioversion:why should we wait?[J]. Expert Rev Cardiovasc Ther,2020,18(3):149-154.
[13].[13] Wijffels MC,Kirchhof CJ,Dorland R,et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats:roles of neurohumoral changes,ischemia,atrial stretch,and high rate of electrical activation[J]. Circulation,1997,96(10):3710-3720.
[14].[14] Dzeshka MS,Lip GY,Snezhitskiy V,et al. Cardiac fibrosis in patients with atrial fibrillation:mechanisms and clinical implications[J].?J Am Coll Cardiol,2015,66(8):943-959.
[15].[15] Jalife J,Berenfeld O,Mansour M. Mother rotors and fibrillatory conduction:a mechanism of atrial fibrillation[J]. Cardiovasc Res,2002,54(2):204-216.
[16].[16] Jaakkola S,Lip GY,Biancari F,et al. Predicting unsuccessful electrical cardioversion for acute atrial fibrillation(from the AF-CVS score)[J]. Am J Cardiol,2017,119(5):749-752.
[17].[17] Naji F,Vokac D,Kanic V,et al. Optimal timing of electrical cardioversion in patients with persistent atrial fibrillation[J]. Med Sci Monit,2010,16(10):CR464-CR468.
[18].[18] Weigner MJ,Thomas LR,Patel U,et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography:short-term safety and impact on maintenance of sinus rhythm at 1 year[J].?Am J Med,2001,110(9):694-702.
[19].[19] Cappato R,Ezekowitz MD,Hohnloser SH,et al. Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation:a pre-planned post hoc analysis of the X-VeRT trial[J].?Europace,2021,23(10):1539-1547.
[20].[20] Jaakkola S,Kiviniemi TO,Airaksinen KEJ. Cardioversion for atrial fibrillation—How to prevent thromboembolic complications?[J].?Ann Med,2018,50(7):549-555.
[21].[21] Nuotio I,Hartikainen JE,Gr?nberg T,et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications[J].JAMA,2014,312(6):647-649.
[22].[22] Brandes A,Crijns HJGM,Rienstra M,et al. Cardioversion of atrial fibrillation and atrial flutter revisited:current evidence and practical guidance for a common procedure[J].Europace,2020,22(8):1149-1161.
[23].[23]You JJ,Singer DE,Howard PA,et al. Antithrombotic therapy for atrial fibrillation:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 suppl):e531S-e575S.
[24].[24] Femia G,Fetahovic T,Shetty P,et al. Novel oral anticoagulants in direct current cardioversion for atrial fibrillation[J].Heart Lung Circ,2018,27(7):798-803.
[25].[25] Warden BA,MacKay J,Jafari M,et al. Use of direct oral anticoagulants among patients undergoing cardioversion:the importance of timing before cardioversion[J].J Am Heart Assoc,2018,7(22):e010854.
[26].[26] Hellman T,Kiviniemi T,Nuotio I,et al. Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation[J]. Thromb Res,2017,156:163-167.
[27].[27] Botto GL,Tortora G. Is delayed cardioversion the better approach in recent-onset atrial fibrillation? Yes[J].Intern Emerg Med,2020,15(1):1-4.
[28].[28] Capucci A,Compagnucci P. Is delayed cardioversion the better approach in recent-onset atrial fibrillation? No[J]. Intern Emerg Med,2020,15(1):5-7.
[29].[29] Abadie BQ,Hansen B,Walker J,et al. Likelihood of spontaneous cardioversion of atrial fibrillation using a conservative management strategy among patients presenting to the emergency department[J].Am J Cardiol,2019,124:1534-1539.
[30].[30] Pluymaekers NA,Hermans AN,Linz DK,et al. Frequency and determinants of spontaneous conversion to sinus rhythm in patients presenting to the emergency department with recent-onset atrial fibrillation:a systematic review[J].?Arrhythm Electrophysiol Rev,2020,9(4):195-201.
[31].[31] Nagarakanti R,Ezekowitz MD,Oldgren J,et al. Dabigatran versus warfarin in patients with atrial fibrillation:an analysis of patients undergoing cardioversion[J].Circulation,2011,123(2):131-136.
[32].[32] Piccini JP,Stevens SR,Lokhnygina Y,et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial[J].J Am Coll Cardiol,2013,61(19):1998-2006.
[33].[33] Flaker G,Lopes RD,Al-Khatib SM,et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation:insights from the ARISTOTLE Trial(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)[J].J Am Coll Cardiol,2014,63(11):1082-1087.
[34].[34] Plitt A,Ezekowitz MD,de Caterina R,et al. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48[J].Clin Cardiol,2016,39(6):345-346.
[35].[35] Connolly SJ,Ezekowitz MD,Yusuf S,et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139-1151.
[36].[36] Patel MR,Mahaffey KW,Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]孙林芳 朱凌燕.老年心房颤动患者抗凝服药依从性及其影响因素分析[J].心血管病学进展,2020,(9):978.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.022]
SUN Linfang,ZHU Lingyan.Compliance with Anticoagulant Medication and Its Influencing Factors in Elderly Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(3):978.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.022]
[12]赵海娟 李珂 赵耀 彭玉霞 黄松群 郭志福.成人先天性心脏病合并心房颤动的诊治进展[J].心血管病学进展,2023,(3):216.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.006]
ZHAO Haijuan,LI Ke,ZHAO Yao,et al.Atrial Fibrillation in Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2023,(3):216.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.006]
[13]杨仙 陈芸霖 殷跃辉 易鑫 杨敏 崔犇.女性乳腺癌相关性心房颤动的研究现状[J].心血管病学进展,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
YANG Xian,CHEN Yunlin,YIN Yuehui,et al.Research Status of Female Breast Cancer Associated Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(3):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]